• Xeris Biopharma struck private exchanges to retire USD 23 million of 8.00% Convertible Senior Notes due 2028.
• Consideration: about USD 23 million cash; remaining value paid in common stock based on a 21-day VWAP starting June 11, 2026.
• At a USD 6.71 reference price, stock issuance would total about 4,600,000 shares.
• Transaction cuts debt by about USD 23 million; annual interest savings estimated at about USD 2 million.
• Notes outstanding expected to fall to USD 10.5 million once the exchanges close.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Xeris Biopharma Holdings Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 202606110700BIZWIRE_USPR_____20260611_BW102458) on June 11, 2026, and is solely responsible for the information contained therein.